Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
1. Veru will present at GLP-1 Therapeutics Summit in April 2025. 2. Positive results from enobosarm's Phase 2b trial show lean mass preservation. 3. Enobosarm enhances fat loss compared to placebo when coupled with semaglutide. 4. Sabizabulin's development focuses on treating inflammation in cardiovascular disease. 5. Safety data for enobosarm remains blinded until the Q2 2025 extension results.